天然产物研究与开发 ›› 2026, Vol. 38 ›› Issue (7): 1570-1580.doi: 10.16333/j.1001-6880.2026.7.019 cstr: 32307.14.1001-6880.2026.7.019

• 数据研究 • 上一篇    下一篇

基于网络药理学和体内实验探讨青柠提取物治疗2型糖尿病的作用机制

黄  逯1,李善良2,谢  鹏1,宁  玲1,莫玉焕1,田  婧1,赵  悦1,黄  宪1*   

  1. 1广西壮族自治区药品检验研究院,南宁 530021;2广西中医药大学,南宁 530200
  • 出版日期:2026-07-24 发布日期:2026-07-23

Mechanism of Citrus aurantiifolia extract in the treatment of type 2 diabetes mellitus based on network pharmacology and in vivo experiments

HUANG Lu1,LI Shan-liang2,XIE Peng1,NING Ling1,MO Yu-huan1,TIAN Jing1,ZHAO Yue1,HUANG Xian1*#br#

#br#
  

  1. 1Guangxi Institute for Drug Control,Nanning 530021,China;2Guangxi University of Chinese Medicine,Nanning 530200,China
  • Online:2026-07-24 Published:2026-07-23

摘要:

基于网络药理学和体内实验探讨青柠提取物(Citrus aurantiifolia extract,CAE)治疗2型糖尿病(type 2 diabetes mellitus,T2DM)作用机制。采用超高效液相色谱仪对CAE中主要成分进行分析,并对橙皮苷、柚皮素、川陈皮素、橘红素等黄酮类成分的含量进行定量检测。应用网络药理学方法预测CAE治疗T2DM作用信号通路。构建高脂饲料喂养及链脲佐菌素诱发T2DM小鼠模型,并使用CAE对T2DM的治疗作用进行动物实验验证,初步验证网络药理学的预测结果。结果显示,从CAE中,检测得到主要成分橙皮苷、柚皮素、川陈皮素、橘红素的含量分别为5.791、0.112、0.523、0.498 mg/g,预测得到此4个成分在治疗T2DM作用靶点有172个,关键靶点10个。GO和KEGG富集分析结果共获得251条通路,主要涉及脂质和动脉粥样硬化、内分泌抵抗、糖尿病并发症中的高级糖基化终末产物-受体(advanced glycation end products-receptor for advanced glycation end products,AGE-RAGE)信号通路等。T2DM小鼠模型实验显示,CAE可显著降低T2DM小鼠血糖、血清低密度脂蛋白、总胆固醇、肌酐、尿素氮的水平,并显著提高血清中高密度脂蛋白的水平。RT-qPCR实验显示,与T2DM组相比,蛋白激酶B(protein kinase B,AKT)mRNA的表达显著升高,糖原合成酶激酶3β(glycogen synthase kinase-3βGSK3β)mRNA的表达显著降低。本研究初步表明CAE可能通过橙皮苷、柚皮素、川陈皮素、橘红素等主要成分,调控AKT/GSK3β通路,发挥调节糖脂代谢紊乱、改善T2DM的作用。

关键词: 青柠提取物, 2型糖尿病, 网络药理学, 体内实验, 作用机制

Abstract:

This study aims to investigate the mechanism of Citrus aurantiifolia extract (CAE) in the treatment of type 2 diabetes mellitus (T2DM) based on the network pharmacological analysis and in vivo experiments. Ultra-high performance liquid chromatography was used to analyze the main components in CAE, and the contents of flavonoids such as hesperidin, naringenin, nobiletin and tangeretin were quantitatively detected. The network pharmacology was employed to predict the potential signaling pathways involved in the treatment of T2DMwith CAE. The T2DM model was induced by high-fat diet combined with streptozotocin. The effect of CAE on T2DM was verified through animal experiments to preliminarily validate the prediction results of network pharmacology. The results showed that the contents of hesperidin, naringenin, nobiletin and tangeretin in CAE were 5.791, 0.112, 0.523 and 0.498 mg/g, respectively. It was predicted that these four components had 172 potential targets for the treatment of T2DM, with 10 key targets. The GO and KEGG enrichment analysis results obtained 251 pathways, mainly involving lipid and atherosclerosis, endocrine resistance, and advanced glycation end products-receptor for advanced glycation end product (AGE-RAGE) signaling pathway in diabetic complications. The experiments on T2DM mice models demonstrated that CAE could significantly reduce the levels of blood glucose, serum low-density lipoprotein, total cholesterol, creatinine, and blood urea nitrogen in T2DM mice, and significantly increase the level of serum high-density lipoprotein. The RT-qPCR experiments showed that compared with the T2DM group, the expression of protein kinase B (AKT) mRNA was significantly increased, while the expression of glycogen synthase kinase-3β (GSK3β) mRNA was significantly decreased. This study preliminarily indicated that CAE might regulate the AKT/GSK3β pathway through the main components such as hesperidin, naringenin, nobiletin and tangeretin, thereby exerting the effects of regulating disordered glucose and lipid metabolism and treating T2DM.

Key words: Citrus aurantiifolia extract, type 2 diabetes mellitus, network pharmacology, in vivo experiments, mechanism

中图分类号:  R285